EP27 - ECE_2912 - Non-functioning adrenal incidentalomas: a diagnosis we can still trust?
Rattachement africain : it, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Introduction Non-functioning adrenal incidentalomas (NFAI) are defined by post–1 mg dexamethasone suppression test (F-1mgDST) cortisol levels <1.8 µg/dL. However, emerging evidence suggests that many individuals classified as having NFAI may exhibit subtle cortisol excess associated with increased cardiometabolic and skeletal risk. Objective To compare F-1mgDST levels between patients with NFAI and control subjects and to identify the F-1mgDST threshold most accurately associated with the presence of NFAI. Materials and Methods Pooled individual participant data analysis of 7 retrospective and prospective studies evaluating cortisol secretion in patients with type 2 diabetes, osteoporosis and/or fragility fractures, hypertension, or adrenal incidentalomas. The study included 1681 participants (915 with NFAI and 766 controls), all with F-1mgDST <1.8 µg/dL. Data collected included age, sex, body mass index (BMI), F-1mgDST, and adrenocorticotroph hormone (ACTH, available for all NFAI patients and for 176 controls). Main outcomes included between-group differences in F-1mgDST and ACTH levels; diagnostic accuracy of F-1mgDST for identifying NFAI via receiver operating characteristic (ROC) analysis; and sensitivity, specificity, and odds ratios (ORs) for predicting NFAI across various F-1mgDST thresholds. Results Compared to controls, patients with NFAI were younger and had lower BMI and ACTH levels but significantly higher F-1mgDST values. ROC analysis demonstrated that an F-1mgDST threshold of 1.1 µg/dL (30 nmol/L) provided the best balance of sensitivity (54.8%) and specificity (57.2%), while an F-1mgDST threshold of 0.6 µg/dL (17 nmol/L) and of 1.7 µg/dL (47 nmol/L) the best sensitivity (93%) and specificity (93.5%), respectively, for distinguishing between control subjects and patients with NFAI. An F-1mgDST >1.1 µg/dL was independently associated with NFAI (OR, 1.58; 95% CI, 1.30–1.92) after adjusting for age, BMI, sex and presence of hypertension, type 2 diabetes and osteoporosis. The combination of obesity and male sex amplified the association, with obese men and F-1mgDST >1.1 µg/dL showing a nearly 3-fold higher likelihood of NFAI (OR, 2.87; 95% CI, 2.02–4.09). Conclusions and Relevance Among individuals with cortisol concentrations within the currently accepted normal range after dexamethasone suppression, those with NFAI display significantly higher F-1mgDST levels than control subjects. These findings indicate that the widely used threshold of 1.8 µg/dL may not reliably exclude mild autonomous cortisol secretion. A lower threshold of 1.1 µg/dL is the may improve identification of individuals with NFAI.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- EP27 - ECE_2912 - Non-functioning adrenal incidentalomas: a diagnosis we can still trust?
- Date Crossref
- 01/08/2026
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Milan pays non établi dans la noticeUniversité ou école supérieure
-
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda pays non établi dans la noticeÉtablissement de santé
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Unit of Endocrinology pays non établi dans la noticeÉtablissement de santé
-
IRCCS Istituto Auxologico Italiano pays non établi dans la noticeÉtablissement de santé
-
Casa Sollievo della Sofferenza pays non établi dans la noticeÉtablissement de santé
-
WinnMed pays non établi dans la noticeOrganisation à but non lucratif
-
ASST Grande Ospedale Metropolitano Niguarda pays non établi dans la noticeInstitution
-
Department & Lab of Endocrine and Metabolic Research pays non établi dans la noticeStructure de recherche
-
Mayo Clinic pays non établi dans la noticeÉtablissement de santé
University of Milan, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda et Unit of Endocrinology — Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.